Daily Cardiology Research Analysis
Three high-impact studies advanced cardiology this cycle: two multicenter AI–ECG works for structural and valvular disease detection/prediction, and a Circulation study defining a 3D aortic vascular aging index with genetic causal links to major cardiovascular diseases. Together, they point to earlier, scalable detection and refined risk stratification that could reshape preventive cardiology and resource allocation for imaging.
Summary
Three high-impact studies advanced cardiology this cycle: two multicenter AI–ECG works for structural and valvular disease detection/prediction, and a Circulation study defining a 3D aortic vascular aging index with genetic causal links to major cardiovascular diseases. Together, they point to earlier, scalable detection and refined risk stratification that could reshape preventive cardiology and resource allocation for imaging.
Research Themes
- AI-enabled ECG for scalable detection and prediction of structural and valvular heart disease
- Imaging-genomics integration to quantify early vascular aging and causal disease links
- Precision prevention and prioritization of echocardiography based on algorithmic risk
Selected Articles
1. Detecting structural heart disease from electrocardiograms using AI.
This multicenter study develops and validates AI models that infer structural heart disease directly from 12‑lead ECGs, offering a low-cost, scalable screening approach when echocardiography access is limited. External validation across health systems supports generalizability and potential triage of patients who most need imaging.
Impact: Repurposing ubiquitous ECGs to detect structural disease could transform early detection, reduce delays to care, and optimize imaging utilization globally. Publishing in Nature underscores the methodological and translational significance.
Clinical Implications: AI–ECG could prioritize echocardiography and specialty referrals, enable opportunistic screening in primary care and low-resource settings, and accelerate diagnosis of structural heart disease. Integration into EHR workflows may help surface silent disease earlier.
Key Findings
- Developed deep learning models that infer structural heart disease directly from standard ECG signals.
- Demonstrated external validation across multiple health systems, supporting generalizability.
- Proposed ECG-first triage to target echocardiography for those at highest risk, potentially improving access and efficiency.
Methodological Strengths
- Multicenter development with external health system validation.
- Leverages widely available ECG data for scalable deployment.
Limitations
- Observational model development without randomized outcome testing.
- Model performance and calibration in low-resource or community settings were not detailed in the abstract.
Future Directions: Prospective impact studies and randomized triage trials comparing AI–ECG-guided pathways versus usual care are needed; fairness assessment and calibration across demographics and devices will be critical.
Early detection of structural heart disease is critical to improving outcomes, but widespread screening remains limited by the cost and accessibility of imaging tools such as echocardiography
2. Early Vascular Aging Determined by 3-Dimensional Aortic Geometry: Genetic Determinants and Clinical Consequences.
Using 3D tomographic aortic geometry from >62,000 scans, the authors created an aortic vascular age index (AVAI) that correlates with adverse cardiac remodeling (e.g., higher LV mass) and shows polygenic heritability. Mendelian randomization supports causal links between early aortic aging and atrial fibrillation, vascular dementia, aortic aneurysm, and aortic dissection.
Impact: This work provides a scalable, imaging-derived vascular aging biomarker linked to causal disease pathways, bridging imaging phenotypes and genetics. It offers a foundation for precision prevention and target discovery in aortic and cardiac disease.
Clinical Implications: AVAI could aid risk stratification for atrial fibrillation and aortopathy, prompting earlier surveillance and preventive interventions. Polygenic insights enable identification of individuals with accelerated vascular aging for targeted lifestyle and medical therapy.
Key Findings
- Defined a sex-specific aortic vascular age index (AVAI) from 3D aortic geometry in 56,104 MRI and 6,757 CT scans.
- Higher AVAI associated with adverse cardiac remodeling, including increased LV mass (standardized β≈0.144).
- GWAS and Mendelian randomization support a causal relationship between AVAI and AF, vascular dementia, aortic aneurysm, and aortic dissection.
Methodological Strengths
- Large-scale, cross-cohort 3D imaging with CNN-assisted segmentation.
- Integrated GWAS, Mendelian randomization, and polygenic risk analyses to probe causality.
Limitations
- Primarily observational; clinical utility thresholds and intervention effects were not tested.
- Imaging cohorts may be healthier/selected, potentially limiting generalizability.
Future Directions: Prospective studies to test whether AVAI-guided surveillance improves outcomes; explore modifiable determinants of AVAI and trials of interventions (e.g., BP control, antihypertensives) to slow aortic aging.
BACKGROUND: Vascular aging is an important phenotype characterized by structural and geometric remodeling. Some individuals exhibit supernormal vascular aging, associated with improved cardiovascular outcomes; others experience early vascular aging, linked to adverse cardiovascular outcomes. The aorta is the artery that exhibits the most prominent age-related changes; however, the biological mechanisms underlying aortic aging, its genetic architecture, and its relationship with cardiovascular structure, function, and disease states remain poorly understood. METHODS: We developed sex-specific models to quantify aortic age on the basis of aortic geometric phenotypes derived from 3-dimensional tomographic imaging data in 2 large biobanks: the UK Biobank and the Penn Medicine BioBank. Convolutional neural network-assisted 3-dimensional segmentation of the aorta was performed in 56 104 magnetic resonance imaging scans in the UK Biobank and 6757 computed tomography scans in the Penn Medicine BioBank. Aortic vascular age index (AVAI) was calculated as the difference between the vascular age predicted from geometric phenotypes and the chronological age, expressed as a percent of chronological age. We assessed associations with cardiovascular structure and function using multivariate linear regression and examined the genetic architecture of AVAI through genome-wide association studies, followed by Mendelian randomization to assess causal associations. We also constructed a polygenic risk score for AVAI. RESULTS: AVAI displayed numerous associations with cardiac structure and function, including increased left ventricular mass (standardized β=0.144 [95% CI, 0.138, 0.149]; CONCLUSIONS: Early aortic aging is significantly associated with adverse cardiac remodeling and important cardiovascular disease states. AVAI exhibits a polygenic, highly heritable genetic architecture. Mendelian randomization analyses support a causal association between AVAI and cardiovascular diseases, including atrial fibrillation, vascular dementia, aortic aneurysms, and aortic dissection.
3. Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.
In >400,000 patients with ~1 million ECG–echo pairs, AI–ECG models predicted future moderate/severe MR, TR, and AR with strong discrimination (e.g., MR C‑index 0.774; TR 0.793). Highest risk quartiles had markedly elevated hazards (MR HR 7.6; TR HR 9.9), and performance replicated in an external US cohort, supporting use to prioritize surveillance echocardiography.
Impact: By forecasting future clinically significant regurgitation from ECG, this study enables earlier, targeted imaging and follow-up, potentially changing surveillance paradigms for valvular disease.
Clinical Implications: Health systems can deploy AI–ECG risk scores to triage who needs timely echocardiography and closer follow-up for MR/TR/AR, improving detection of progression before symptoms and optimizing resource use.
Key Findings
- Internal discrimination for future significant regurgitation: MR C-index 0.774, AR 0.691, TR 0.793.
- Top risk quartile vs. lowest showed markedly higher hazards: MR HR 7.6; AR HR 3.8; TR HR 9.9.
- External validation in a distinct US cohort (n=34,214) reproduced performance; ECG risk associated with subclinical chamber remodeling.
Methodological Strengths
- Very large development set (~988,618 ECG–echo pairs) with external validation in a transnational cohort.
- Use of survival-aware deep learning (discrete-time survival loss) aligned with time-to-event prediction.
Limitations
- Observational design; no randomized evaluation of AI-guided surveillance pathways.
- Performance in primary care and low-resource settings or with heterogeneous ECG devices requires further study.
Future Directions: Prospective trials to test whether AI–ECG–guided echocardiography improves time to diagnosis and outcomes; calibration/fairness across demographics and comorbidities; health economic analyses.
BACKGROUND AND AIMS: Valvular heart disease (VHD) is a significant source of morbidity and mortality, though early intervention can improve outcomes. This study aims to develop artificial intelligence-enhanced electrocardiography (AI-ECG) models to diagnose and predict future moderate or severe regurgitant VHDs (rVHDs), including mitral regurgitation (MR), tricuspid regurgitation (TR), and aortic regurgitation (AR). METHODS: The AI-ECG models were developed in a data set of 988 618 ECG and transthoracic echocardiogram pairs from 400 882 patients from Zhongshan Hospital, Shanghai, China. The AI-ECG models used a residual convolutional neural network with a discrete-time survival loss function. External evaluation was performed in outpatients from a secondary care data set from Beth Israel Deaconess Medical Center, Boston, USA, consisting of 34 214 patients with linked echocardiography. RESULTS: In the internal test set, the AI-ECG models accurately predicted future significant MR [C-index 0.774, 95% confidence interval (CI) 0.753-0.792], AR (0.691, 95% CI 0.657-0.720), and TR (0.793, 95% CI 0.777-0.808). In age- and sex-adjusted Cox models, the highest risk quartile had a hazard ratio (HR) of 7.6 (95% CI 5.8-9.9, P < .0001) for risk of future significant MR, compared with the lowest risk quartile. For future AR and TR, the equivalent HRs were 3.8 (95% CI 2.7-5.5) and 9.9 (95% CI 7.5-13.0), respectively. These findings were confirmed in the transnational external test set. Imaging association analyses demonstrated AI-ECG predictions were associated with subclinical chamber remodelling. CONCLUSIONS: This study developed AI-ECG models to diagnose and predict rVHDs and validated the models in a transnational and ethnically distinct cohort. The AI-ECG models could be utilized to guide surveillance echocardiography in patients at risk of future rVHDs, to facilitate early detection and intervention.